Conditions: Pulmonary Disease, Chronic Obstructive
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 32
Healthy volunteers: no

Brief summary:
The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the RESPIMAT inhaler after 3 weeks once daily treatment in Japanese patients with COPD.

Detailed description:

Arms:
arm 1: Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT arm 2: Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT

Interventions: intervention 1: Tiotropium (high dose) + Olodaterol intervention 2: Tiotropium (low dose) + Olodaterol
Intervention descriptions: intervention 1: Tiotropium + Olodaterol solution for inhalation intervention 2: Tiotropium + Olodaterol solution for inhalation

Protocol document: